FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma
Authors:
Open Access
- 13 October 2021
- journal article
- research article
- Published by Springer Nature in Cancer Imaging
- Vol. 21 (1) , 1-6
Abstract
Background: The role of FDG-PET/CT imaging in assessing response to immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) is unknown. This study compared complete metabolic response (CMR) rates by FDG-PET and RECIST1.1 via CT or MRI in patients on cemiplimab for > 10 months. Methods: This was a single-centre retrospective study of 15 patients treated with cemiplimab for advanced CSCC who had CT/MRI and FDG-PET/CT at > 10 months to assess metabolic treatment response. The median age was 73 years (range 55–84) and 93% were male. RECIST1.1 and PERCIST1.0 tumor responses were evaluated by blinded readers. Results: Seventy-three percent (11/15) (95%CI 44.9, 92.2%) achieved a CMR on PET. Of these 11, on RECIST1.1 there was one complete response, 9 partial responses and one stable disease. Conclusions: In patients on cemiplimab for > 10 months, there was discordance between CR rates on FDG-PET versus RECIST1.1. FDG-PET/CT may have utility for clarifying depth of response in patients treated with immunotherapy for CSCC.Keywords
Funding Information
- National Health and Medical Research Council (NHMRC Investigator Grant APP1175929)
This publication has 20 references indexed in Scilit:
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2018
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer ImmunotherapyJournal of Clinical Oncology, 2018
- Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reportsJournal for ImmunoTherapy of Cancer, 2018
- The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and ImmunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsThe Lancet Oncology, 2017
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional MeasurementsClinical Cancer Research, 2013
- Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with ErlotinibClinical Cancer Research, 2011
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009